Project description DEENESFRITPL Innovative computer-controlled device for the emergency treatment of cardiac arrest Sudden cardiac arrest (SCA) is a life-threatening condition with a high mortality rate. Immediate rescue procedures can help, but the risk of severe brain tissue damage due to insufficient oxygen supply to cells is high. Denmark-based company Neurescue has developed a game-changing device that increases coronary and cerebral perfusion pressure in the patient, improving the likelihood of response to defibrillation and increasing blood flow to the brain. The EU-funded CAtALySt project aims to perform clinical validations in hospitals in Germany and the United States involving a total of 20 SCA patients. The project will create an open-access data platform that can support information exchange between clinicians and will establish a distribution network in the different regional markets. Show the project objective Hide the project objective Objective With a worldwide incidence expected to increase from 9,23 million cases by 2020 to 10,89 million cases by 2030, Sudden Cardiac Arrests (SCA) episodes are today recognized as a public health problem leading to severe brain tissue damage with survival rates below 10%. Neurescue Aps (NEUR) proposes to address the SCA burden by bringing to light a game changing solution - NeurescueTM – capable of extending the critical time window necessary to bring a SCA patient back to normal heart function, and therefore holding the potential to radically improve the emergency assistance provided to SCA patients, allowing for 20- 40% of increase in the survival rate of SCA patients. Due to an algorithm-run sensor technology which enables a safe and accurate computer-controlled aortic occlusion, NeurescueTM is a portable medical device that, not only increases the blood perfusion pressure necessary for vital organs preservation (i.e. brain and heart), but also works in synergy with standard resuscitation procedures increasing their probability of success. NeurescueTM is the only device in the market that combines portability with the accuracy required for a safe medical intervention (i.e. aorta occlusion) to SCA patients both inside and outside the hospital premises. With a price-competitive technology and with an unrivalled value proposition, NEUR is in a strong position to build a profitable business. Building on the project activities, NeurescueTM the device is projected to be ready for commercial roll-out by 2021 with a predicted total aggregated revenue for the company of over €234M throughout the 5 years post- project. CAtALySt project aims to surpass the main market barriers associated with the market introduction of NeurescueTM, namely obtaining FDA clearance, gathering data for CE-marking and broad clinical demonstration for market awareness and to ensure end-user medical adoption. Pre-clinical validation will be completed with Heidelberg University Hospital in Germany on 10 in-hospital cardiac arrest patients, and with MemorialCare Heart Institure in Los Angeles, USA on 10 in-hospital cardiac arrest patients. Fields of science medical and health sciencesclinical medicineanaesthesiology Keywords Sudden Cardiac Arrests Medical device Computer-controlled aortic occlusion Vital organs preservation Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-2 Funding Scheme SME-2 - SME instrument phase 2 Coordinator NEURESCUE APS Net EU contribution € 1 632 251,25 Address NJALSGADE 76 2300 Kobenhavn Denmark See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Danmark Hovedstaden Byen København Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 2 331 787,50